The trial consisted of 37 patients with moderate-to-severe COPD, who received a single dose of either the drug or a placebo.
News
Tecentriq, chemo combo shows bladder cancer promise
Tecentriq was the first cancer immunotherapy approved in bladder cancer.
Rivipansel flunks Phase III sickle cell trial
The trial was for patients six and older with the disease who required treatment with IV opioids for occlusive crisis.
New blood test ‘highly accurate’ at early Alzheimer’s identification
The test can measure levels of the Alzheimer’s protein amyloid beta in the blood.
Emgality ‘CONQUER’s in late-stage migraine trial
Treatment with Emgality reduced monthly migraine headache days by 4.1 days.
Dupixent hits endpoints in paediatric trial
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
The Sales Awards Chair explains what makes the 2019 competition so beneficial & rewarding
The Chair of the 2019 Sales Awards, David Garmon-Jones, shares his thoughts on what makes this competition such an exciting and worthwhile experience.
Flu vaccine could reduce risk of death for elderly patients
For those who were vaccinated the risk of suffering a stroke was 16% lower than those who weren’t.
Turalio becomes first FDA-approved treatment for tenosynovial giant cell tumour
GCT is a rare tumour that affects the synovium and tendon sheaths.
AZ’ Forxiga label updated in EU for type II diabetes
The decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial.
Sosei Heptares, Takeda embark on strategic R&D partnership
The collaboration will combine Sosei’s structure-based drug design capabilities with Takeda’s discovery, development and therapeutic area expertise.
New PM pledges £1.8bn to NHS
The 20 hospitals set to be upgraded at a cost of £850 million have been announced.
A broad range of companies have committed to the 2019 Communications Team of the Year competition
With the entries for the 2019 competition well underway, PharmaTimes have seen a large number of industry leading companies putting their best teams and individuals forward.
FDA grants Opdivo combo Breakthrough Designation for melanoma
Bempegaldesleukin, Nektar’s lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist.
Nucala receives self-administration EU approval
It is the only monthly anti-IL5 biologic approved in Europe that patients can take home.
